Comparative Pharmacology
Head-to-head clinical analysis: ACETOHEXAMIDE versus DYMELOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACETOHEXAMIDE versus DYMELOR.
ACETOHEXAMIDE vs DYMELOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin release from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels (K_ATP), causing membrane depolarization, calcium influx, and exocytosis of insulin-containing granules. Also may increase peripheral insulin sensitivity.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
Initial: 250 mg orally once daily; maintenance: 250-1500 mg orally once daily or in divided doses twice daily.
Initial dose: 250 mg orally once daily with breakfast; maintenance dose: 250-500 mg orally once daily; maximum dose: 1000 mg per day.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours (parent drug); ~5-6 hours (active metabolite hydroxyhexamide); clinical context: prolonged in renal impairment due to accumulation of active metabolite
Terminal elimination half-life is 6-10 hours; clinically significant as it supports once-daily dosing.
Renal: 85-90% (60-70% as unchanged drug, remainder as hydroxylated metabolite); biliary/fecal: <10%
Primarily renal excretion of metabolites and unchanged drug (approximately 70-80%), with biliary/fecal excretion accounting for 10-20%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic